ITCI Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m. ET in Boston, MA.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit .

Contact:

Intra-Cellular Therapies, Inc.

Juan Sanchez, M.D.

Vice President, Corporate Communications and Investor Relations

646-440-9333

Burns McClellan, Inc.

Cameron Radinovic



646-930-4406



EN
08/08/2024

Underlying

ITCIIntra-Cellular Therapies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intra-Cellular Therapies Inc.

 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results,...

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA’s strong prescription uptake continues: Q3 2024 CAPLYTA total prescriptions increased 38%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance range raised to $665 to $685 million Following a successful pre-supplemental NDA (sNDA) meeting with the U.S. Food and Drug Administrati...

15h / 52m 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results ...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, October 30, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2024. To atten...

October 17, 2024 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies Announces Presentations at the 2024 European ...

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster presentations of post-hoc analyses from Study 403 including the prespecified patient population with MDD or bipolar depression with mixed features who also had anxious distress NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical ...

September 23, 2024 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies to Present at Three Upcoming Investor Confere...

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare ConferenceWednesday, September 4, 2024 at 10:00 a.m. ET in New York, NY Baird’s 2024 Global Healthcar...

August 28, 2024 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annu...

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m. ET in Boston, MA. The live and archived webcast can be accessed under "Eve...

August 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch